PRH/HHex (proline-rich homeodomain protein) is a transcription factor that controls cell proliferation and cell differentiation in a variety of tissues. Aberrant subcellular localisation of PRH is associated with breast cancer and thyroid cancer. Further, in blast crisis chronic myeloid leukaemia, and a subset of acute myeloid leukaemias, PRH is aberrantly localised and its activity is downregulated. Here we show that PRH is involved in the regulation of cell migration and cancer cell invasion. We show for the first time that PRH is expressed in prostate cells and that a decrease in PRH protein levels increases the migration of normal prostate epithelial cells. We show that a decrease in PRH protein levels also increases the migration of normal breast epithelial cells. Conversely, PRH overexpression inhibits cell migration and cell invasion by PC3 and DU145 prostate cancer cells and MDA-MB-231 breast cancer cells. Previous work has shown that the transforming growth factor-b co-receptor Endoglin inhibits the migration of prostate and breast cancer cells. Here we show that PRH can bind to the Endoglin promoter in immortalised prostate and breast cells. PRH overexpression in these cells results in increased Endoglin protein expression, whereas PRH knockdown results in decreased Endoglin protein expression. Moreover, we demonstrate that Endoglin overexpression abrogates the increased migration shown by PRH knockdown cells. Our data suggest that PRH controls the migration of multiple epithelial cell lineages in part at least through the direct transcriptional regulation of Endoglin. We discuss these results in terms of the functions of PRH in normal cells and the mislocalisation of PRH seen in multiple cancer cell types.
INTRODUCTION
The transcription factor PRH (proline-rich homeodomain/HHex) is essential for formation of the vertebrate body axis and the development of most organs including the heart, thyroid, pancreas, vasculature and haematopoietic compartment. 1 PRH can activate or repress transcription of its target genes and it can also control gene expression at the post-transcriptional level via a protein-protein interaction with eIF4E. [2] [3] [4] [5] In the mouse, retroviral expression of PRH leads to a T-cell leukaemia. 6 Moreover, in human T-cell leukaemias associated with the aberrant expression of the LMO2 oncogene, elevated PRH expression is necessary for development of the disease. 7, 8 However, more generally, it is the disruption of PRH activity that is associated with a variety of diseases states. [9] [10] [11] [12] Aberrant subcellular localisation of PRH with loss of nuclear PRH is associated with blast crisis chronic myeloid leukaemia and some subtypes of acute myeloid leukaemia. 12 Further, in one human acute myeloid leukaemia the only characterised genetic change is a fusion of the prh gene with the nucleoporin gene Nup98 and this is thought to decrease the activity of endogenous PRH. 11 We have shown that in a chronic myeloid leukaemia cell line, BCR-ABL activity indirectly results in the downregulation of PRH transcriptional repression activity and the de-repression of several PRH target genes including Vegfa, Vegfr-1 and Vegfr-2. 13 The repression of these genes in chronic myeloid leukaemia K562 cells by PRH results in decreased vascular endothelial growth factor (VEGF) autocrine signalling and decreased cell survival. 13 Conversely, inactivation or downregulation of PRH and the consequent de-repression of these genes results in increased cell survival. Significantly, decreased nuclear PRH protein is also associated with breast and thyroid tumours. 9, 10 Endoglin is a transforming growth factor (TGF)-b co-receptor that modulates TGF-b-dependent cellular responses. 14, 15 Most studies on Endoglin have focused on its pro-angiogenic role in endothelial cells, its involvement in vascular remodelling and its role as a marker of the tumour vasculature, but it also has a direct role in tumorigenesis. 16 Several studies have concluded that decreased Endoglin expression is associated with prostate cancer cell migration. For example, Endoglin expression was found to be lower in multiple cancer cell lines than in immortalised normal prostate cells and downregulation of Endoglin expression was shown to increase prostate cancer cell migration and invasion. 17 More recent data have shown that decreased Endoglin levels in prostate cancer cells result in increased metastasis and increased tumour size. 18 The inhibition of prostate cell migration by Endoglin occurs through the activation of TGF-b co-receptor signalling and the consequent phosphorylation of Smad1, as well as through a Smad1-independent pathway. 19, 20 Endoglin has also been shown to inhibit invasion and colony formation by oesophageal epithelial cells 21 and to suppress cancer formation by skin epithelial cells. 22 Moreover, Endoglin inhibits the migration and invasion of breast tumour cells in vivo by modulating cytoskeletal remodelling rather than through TGFb co-receptor 1 Division of Immunity and Infection, School of Medicine, University of Birmingham, Edgbaston, Birmingham, UK and modulation and low Endoglin expression correlates with poor prognosis in a panel of invasive breast tumours. 23 Interestingly, PRH overexpression has been demonstrated to inhibit angiogenesis but to increase Endoglin mRNA and protein levels in human endothelial cells. 24 However, it is not known whether Endoglin is a direct target for transcriptional regulation by PRH in these cells. It is also unknown whether the regulation of Endoglin by PRH occurs in other cell types and whether this could be important in tumorigenesis. Here we show that PRH regulates the migration of normal prostate and breast epithelial cells and that PRH overexpression inhibits migration and invasion of prostate and breast tumour cells. Our findings suggest that in prostate cancer cells and breast cancer cells the regulation of Endoglin by PRH may be attenuated resulting in increased cell migration and cell invasion.
RESULTS
PRH regulates cell migration PNT2-C2 cells are a normal immortalised prostate epithelial cell line. 25, 26 Western blotting reveals that PNT2-C2 cells express PRH ( Figure 1a ). To determine whether PRH has an important role in these cells, we performed a PRH knockdown experiment using specific short hairpin RNAs (shRNAs). PNT2-C2 cells were transfected with plasmids expressing PRH shRNA and selected in puromycin for 10 days. Western blotting confirms that PRH protein levels are significantly reduced in the PRH knockdown cells (PNT2-C2 KD cells) compared with cells expressing a control shRNA (Figures 1a and b) . To determine whether the PNT2-C2 PRH KD cells exhibit increased cell motility, we performed wound closure assays. Confluent layers of PNT2-C2 KD cells and control cells were wounded with a pipette tip and wound closure monitored over time using microscopy ( Figure 1c) . Interestingly, PNT2-C2 KD cells migrate into the wound significantly faster than control cells (Figure 1d ). This experiment was performed in the presence of hydroxyurea to inhibit cell division and ensure that any effects of PRH knockdown on cell proliferation could not account for changes in cell migration. To investigate the effects of PRH on chemotaxis, we placed PNT2-C2 KD cells and control transfected cells in Boyden chambers and determined the number of cells that migrate towards high serum. After 4 h, significantly more PNT2-C2 KD cells than control cells migrate towards high serum (Figure 1e ). Taken together, these data show that PRH is expressed in prostate epithelial cells and that PRH knockdown increases cell migration.
PRH overexpression inhibits prostate cancer cell migration and invasion To determine whether PRH also influences the migration of tumour cells, we overexpressed PRH in PNT2-C2 cells and two well-characterised prostate cancer cell lines, PC3 cells and DU145 cells. We transfected each cell line with a vector expressing green fluorescent protein (GFP) or with a GFP expression vector in combination with a PRH expression vector and we used GFP as a marker to follow the migration of transfected cells. In each case, overexpression of PRH brings about a significant reduction in cell migration (Figure 2a) . We also examined the effects of PRH Figure 1 . PRH regulates cell motility. (a) PNT2-C2 cells were transfected with plasmids expressing PRH shRNAs or a control shRNA and grown for 10 days in puromycin selection. Western blotting of day 10 whole-cell extracts was performed using a monoclonal antibody that recognises PRH. The two bands detected represent hyper-and hypophosporylated PRH. 42 Antibodies that recognise Tubulin confirm equal loading. (b) PRH protein levels in three independent experiments after 10 days in selection were quantified relative to Tubulin. Figure S1A) . They also showed a significant reduction in migration velocity and displacement (Supplementary Figures S1B and C, respectively). To determine whether the transcriptional activity of PRH is required to inhibit cell migration, we expressed two PRH mutants in these cells. PRH N187A contains a mutation in the PRH homeodomain and is unable to bind DNA. 4, 27 PRH F32E contains a mutation that blocks the binding of PRH to co-repressor proteins belonging to the TLE family. 3, 27 Both of these mutated proteins show a significantly reduced ability to inhibit cell migration compared with wild-type PRH (Figure 2b ), although all three proteins are expressed at roughly equivalent levels ( Figure 2c ). This suggests that PRH inhibits cell migration via the transcriptional regulation of PRH target genes.
We next set out to determine whether PRH inhibits cancer cell invasion and extravasation. PNT2-C2 cells are normal immortalised cells that cannot invade a Matrigel layer; however, PC3 cells and DU145 cells expressing GFP alone are able to migrate through a Matrigel layer. In contrast, tumour cells expressing both GFP and PRH show a significant reduction in invasion (Figure 2d ). Further, in extravasation assays, PC3 cells expressing PRH show a significant reduction in their ability to traverse a layer of endothelial cells placed over Matrigel (Figure 2e ).
PRH directly activates transcription of Endoglin
To determine whether PRH regulates Endoglin expression in normal prostate cells and prostate cancer cells, we used quantitative reverse transcriptase-mediated PCR to measure Endoglin mRNA levels in PNT2-C2 cells and PC3 cells. We infected the cells with an empty adenovirus or with an adenovirus that expresses Myc-tagged PRH (Ad PRH). 28 In both PNT2-C2 cells and PC3 cells infection with Ad PRH brings about a significant increase in Endoglin mRNA levels ( Figure 3a) . Endoglin protein levels are also increased in cells overexpressing PRH (Figure 3b ). Conversely, Endoglin protein levels are significantly reduced in PNT2-C2 cells in which PRH has been knocked down using shRNA (Figure 3c ). Figures S2A and B) . The Endoglin promoter contains several putative PRH-binding sites both proximal and distal to the transcription start site. To determine whether PRH binds to the Endoglin promoter, we performed chromatin immunoprecipitation (ChIP) experiments. PNT2-C2 cells were infected with Ad PRH and chromatin from these cells was isolated and sheared by sonication. ChIP using a Myc antibody was then used to isolate DNA fragments bound to Myc-PRH. PCR with a primer pair specific for Endoglin promoter sequences from À 1042 to À 551 relative to the transcription start point (Figure 3d ) indicates that PRH binds at or near this region (P1 in Figure 3d ). This region contains three putative PRH-binding sequences as defined by the presence of 5 0 -TAAT-3 0 motifs. Promoter sequences flanking a previously characterised enhancer 29,30 located 8 kb upstream of the transcription start point also contain multiple putative PRH-binding sites. Primer pairs specific for promoter sequences from À 7352 to À 6914 and À 8857 to À 8398 (which contain one and six putative PRH-binding sites, respectively) show that PRH can also bind in these regions in PNT2-C2 cells (P3 and P4 in Figure 3d ). This binding is unlikely to be an artefact of PRH overexpression as a primer pair specific for promoter sequences from À 1547 to À 1353 that lacks putative PRH sites fails to produce a product (P2 in Figure 3d) . Moreover, the PRM2 gene is highly expressed in tumour cells and primer pairs for this locus were used as a control to show that there is little nonspecific enrichment of sequences from elsewhere in the genome using these conditions.
Reporter assays using a series of Endoglin promoter fragments cloned upstream of the luciferase gene confirm that sequences between À 851 and À 400 are responsive to PRH overexpression (Supplementary Figure S3B) . However, unexpectedly, PRH overexpression represses the activity of Endoglin reporter constructs that contain this PRH-responsive region. This suggests that activation of the endogenous Endoglin promoter by PRH is complex and that it might require the presence of chromatin/ chromatin associated factors or that activation is mediated by the promoter distal PRH-binding sites identified above using ChIP.
Endoglin overexpression inhibits the increased migration of PRH knockdown cells The data shown above suggest that PRH inhibits cell migration by the direct transcriptional regulation of Endoglin. To investigate this Endoglin protein levels in whole-cell extracts prepared from the cells described in a were determined using western blotting. Antibodies that recognise Tubulin confirm equal loading. Bottom: the graph shows Endoglin protein levels in the cells described above determined using densitometry. M þ s.d., n ¼ 3. *Po0.01. (c) Top: Endoglin protein levels in whole-cell extracts prepared from control PNT2-C2 cells 1 and PRH knockdown PNT2-C2 cells 2 at day 10 in selection were determined using western blotting. Antibodies that recognise Lamin A/C confirm equal loading. Bottom: the graph shows Endoglin protein levels in PRH knockdown PNT2-C2 cells compared with control PNT2-C2 cells. M þ s.d., n ¼ 4. **Po0.01. (d) Upper panel: a cartoon of the Endoglin promoter region, showing the transcription start point (bent arrow) and primers used for ChIP. Lower panel: Myc-PRH was expressed in PNT2-C2 cells using Ad PRH. ChIP was then performed as described in the text. Each panel shows the result of PCR with primer pairs P1-P4 and input chromatin, 1 chromatin precipitated with IgG, 2 Myc antibody 3 or a no template control.
in more detail, we overexpressed Endoglin in prostate cells (Supplementary Figure S4A) . As expected, overexpression of Endoglin inhibits migration (Supplementary Figure S4B) and invasion by PC3 cells and DU145 cells (Supplementary Figure  S4C) . As mentioned earlier, PNT2-C2 PRH knockdown cells show increased cell migration. Overexpression of Endoglin in PNT2-C2 PRH knockdown cells completely abrogates the increased migration of these cells in wound closure assays (Figure 4a ). Moreover, although overexpression of Endoglin has little or no effect on chemotaxis by PNT2-C2 cells (Figure 4b ), Endoglin overexpression completely abolishes the increased chemotaxis shown by PNT2-C2 PRH knockdown cells (Figure 4b, lanes 3 and 4) . We conclude that the effects of Endoglin on cell migration are downstream from PRH. This suggests that PRH does indeed inhibit cell migration through the direct regulation of Endoglin expression.
To investigate whether TGFb signalling is involved in the control of cell migration by PRH, we made use of a specific inhibitor that targets TGFb superfamily type I activin receptor-like kinase (ALK) receptors ALK4, ALK5 and ALK7. The inhibition of TGFb signalling abrogates the negative effects of PRH overexpression on the migration of DU145 cells (Figure 4c) . Further, inhibition of TGF-b signalling also abrogates the negative effects of Endoglin overexpression on the migration of these cells (Figure 4c ). As expected, the levels of phosphorylated Smad3, a downstream target for TGF-b-induced phosphorylation, are reduced in the treated cells (Figure 4d ). This indicates that both PRH and Endoglin inhibit prostate cell migration through the downregulation of TGFb signalling.
PRH inhibits the migration of normal breast epithelial cells and breast cancer cells As PRH is known to be aberrantly localised in breast cancer cells, 9 we next set out to determine whether this protein also controls the migration of normal breast epithelial cells and breast cancer cells. We knocked down PRH in normal immortalised breast epithelial MCF10A cells using a lentivirus expressing an isopropyl b-D-1-thiogalactopyranoside-inducible shRNA against PRH (Figure 5a ). Interestingly, three independent PRH knockdown cell lines show a significant increase in chemotaxis compared with controls ( Figure 5b) . To investigate the effects of PRH on breast cancer cell migration and cell invasion, we made use of two wellcharacterised breast cancer cell lines: MCF-7 cells, an oestrogen receptor-positive breast adenocarcinoma cell line, and MDA-MB-231 cells, a hormone-independent breast adenocarcinoma cell line. We infected these cells with Ad PRH or empty adenovirus and examined the effects on cell migration in scratch wound assays. In both cases, cells infected with Ad PRH show a decrease in wound closure (Supplementary Figure S5A) . In chemotaxis experiments, infection with Ad PRH results in a significant reduction in cell migration in both cell lines (Figure 5c ). To confirm that this reduction in cell migration is not due to adenoviral infection, we also examined the migration of MCF-7 PRH knockdown cells (Figure 5a, right) . Three independent MCF-7 cell lines transduced with lentiviruses expressing PRH shRNA exhibit a significant increase in wound closure (Figure 5d ). We next transiently transfected MDA-MB-231 cells with a vector expressing GFP or with GFP and PRH expression vectors and performed invasion Figure 5 . PRH regulates breast cancer cell migration and invasion. (a) MCF10A cells and MCF-7 cells were transduced using a control lentivirus that activates RNA-induced silencing complex and the RNA interference pathway but does not target any known gene 1 or a lentivirus expressing PRH shRNA. 2 shRNA expression was then induced using isopropyl b-D-1-thiogalactopyranoside for 7 days. Western blotting of whole-cell extracts was performed using a monoclonal antibody that recognises PRH and antibodies that recognise Tubulin or Lamin A/C. Figures S5B  and C) . To examine whether the ability of PRH to influence the migration of MCF10A cells and breast cancer cells also involves the regulation of Endoglin, we measured Endoglin mRNA levels in MCF-7 and MCF10A cells overexpressing PRH. In both cases, PRH overexpression results in a significant increase in Endoglin mRNA (Figure 5f ). Moreover, Endoglin protein levels are decreased in PRH knockdown MCF10A cells (Figure 5g) . The effects of PRH on Endoglin mRNA and protein expression appear to be direct, as ChIP of Myc-tagged PRH pulls down Endoglin promoter sequences in both MCF-7 and MCF10A cells (Supplementary Figure S5D) . These data suggest that PRH inhibits the migration of normal breast cells and breast cancer cells via transcriptional regulation of Endoglin expression.
DISCUSSION
The ability of PRH/HHex to control cell proliferation and cell differentiation in multiple cell types is well documented. PRH can control cell proliferation via the post-transcriptional regulation of cyclin D mRNA transport. 2 In addition, our previous work has shown that in leukaemic cells, PRH directly represses multiple genes that encode proteins involved in VEGF signalling including Vegfa and Vegfr-1. 31 In these cells, VEGF acts as an autocrine growth factor and the transcriptional regulation of these VEGFsignalling genes by PRH controls cell survival. The extent to which these modes of cell survival control operate in other cell types is not known, although in breast cancer MCF-7 cells, PRH regulates the transcription of Vegf receptor genes and a PRH knockdown increases cell growth. 31 In endothelial cells, PRH overexpression also controls VEGF-signalling genes and alters cell migration and invasion. 24 In breast and thyroid cancer cells, PRH subcellular localisation is altered resulting in the cytoplasmic and nucleolar accumulation of PRH. 9, 10 However, the ability of PRH to regulate other aspects of cancer cell behaviour relevant to tumorigenesis, including cell motility and cell invasion, has not been investigated.
Here we have shown that PRH knockdown increases the motility of immortalised prostate and breast epithelial cells and increases chemotaxis by these cells. Conversely, PRH overexpression decreases cell migration by prostate and breast cancer cells and inhibits the ability of these cells to invade a Matrigel layer. Moreover, PRH overexpression decreases the ability of prostate cancer cells to travel though a layer of endothelial cells in extravasation assays. These findings suggest that the aberrant localisation of PRH seen in breast cancer cells and thyroid cancer cells could contribute to their increased migration and cell invasion as well as having effects on cell proliferation. Moreover, these results show that PRH activity is important in the control of these aspects of cell behaviour in normal epithelial cells, and they suggest that PRH may also be aberrantly localised or otherwise misregulated in prostate cancer cells.
Knockout of PRH in embryoid bodies results in downregulation of Endoglin mRNA, 32 and PRH overexpression has been shown to upregulate Endoglin mRNA and protein levels in endothelial cells. 24 We have shown that PRH associates directly with the Endoglin promoter and upregulates transcription of Endoglin in normal prostate and breast epithelial cells and prostate and breast cancer cell lines. PRH binds to DNA sequences within the Endoglin proximal promoter located around 500 bp upstream of the transcription start point and upstream of a number of important transcription factor-binding sites including sites for regulation by Sp1, HIF-1, Smad proteins, KLF6 and ETS family members. 30, [33] [34] [35] PRH also binds to sequences in the distal promoter near a previously characterised enhancer 29, 30 around 8 kb upstream of the transcription start point. These regions both contain multiple copies of the core PRH-binding site 5 0 -TAAT-3 0 . Other PRH target genes including Goosecoid, Vegfr-1 and Vegfa also contain arrays of PRH core binding sites and at these promoters PRH also binds over extensive regions. 36, 37 This suggests that PRH oligomers bind to these promoters in a similar manner in order to control promoter architecture. However, at other promoters, PRH binds in conjunction with other transcription factors and in these cases extensive direct contacts between PRH and the DNA may not be required.
1 Surprisingly, although the promoter proximal binding sites in the Endoglin promoter confer responsiveness to PRH overexpression in luciferase assays, PRH appears to repress Endoglin transcription when bound at these sites. Presumably, the promoter distal PRH-binding sites are responsible for Endoglin transcription activation by PRH. Alternatively, the presence of chromatin/chromatin associated factors may be important for activation of the Endoglin promoter by PRH just as they are for repression by PRH at the Vegfr-1 promoter. 31 Further experiments will be required to determine the mechanisms that PRH uses in order to activate transcription at this promoter.
Importantly, the increased cell migration shown by PRH knockdown cells is completely abolished by Endoglin overexpression. We conclude that in both breast and prostate cells, PRH regulates Endoglin expression and that the effects of PRH on cell migration are in part at least through the control of this target gene. Endoglin has been shown to inhibit cell migration, cell invasion and tumour growth by prostate cancer cells and cell migration and invasion of breast cancer cells. 18, 23 However, it has been reported that Endoglin expression is higher in metastatic cancer epithelial cells and prostatic intraepithelial neoplasia compared normal prostate cells. 38 Moreover, in highly metastatic breast cancer cells, increased Endoglin expression is associated with invasion and metastasis. 39 It would seem likely that the effects of Endoglin overexpression may depend on the cell type and/or the overexpression level as well as interplay between the tumour and the stroma and inputs from multiple signalling pathways. However, we have observed decreased Endoglin expression in prostate tumour cells and breast tumour cells relative to immortalised cells. Henry et al. 23 also reported decreased Endoglin expression in most breast tumour cell lines relative to immortalised cells and detected Endoglin expression in only a minority of primary tumours. We expect that the regulation of Endoglin by PRH is disrupted in breast cancer cells. Further experiments will be required to determine whether PRH activity in prostate cancer cells is disrupted by changes in PRH localisation as has been observed in breast cancer cells 9 or by some other mechanism. However, it would seem probable that in both of these cancer types and in other cancer cells in which PRH is aberrantly localised, the loss of PRH activity may contribute to increased cell invasion, increased cancer metastasis and ultimately, decreased patient survival in part at least through a decrease in Endoglin expression. Loss of PRH activity would also be expected to de-repress VEGF-signalling genes resulting in increased cell survival and/or increased neoangiogenesis. This combination of outcomes arising from the loss of PRH activity suggests that this protein has a critical role in tumourigenesis.
MATERIALS AND METHODS

Expression vectors and reporters
pMUG1-Myc-PRH expresses human PRH tagged with the Myc9E10 epitope.
3 pMUG1-Myc-PRH N187A and pMUG1-Myc-PRH F32E express mutated PRH proteins that fail to bind DNA and TLE, respectively. 3 The plasmids shRNAPRH49 and shRNAPRH51 and control shRNA plasmid were obtained from Origene (Rockville, MD, USA). The Endoglin expression vector pcDNA3.1-Endoglin (long isoform) was a gift from Professor Clare Isacke. The recombinant adenoviral construct expressing Myc-PRH has been described previously.
28 pCD105( À 2450/ þ 350), pCD105( À 851/ þ 350) and pCD105( À 400/ þ 350) containing Endoglin promoter sequences cloned upstream of the firefly luciferase gene were a gift from Professor Carmelo Bernabeu. 34, 35 pRL-CMV expressing Renilla luciferase was purchased from Promega (Madison, WI, USA). Lentiviral constructs expressing isopropyl b-D-1-thiogalactopyranoside-inducible PRH shRNA or a control shRNA were obtained from Sigma (Gillingham, UK).
Cell culture PNT2-C2, PC3, DU145, MCF-7 and MDA-MB-231 cells were cultured in Roswell Park Memorial Institute medium-1640 supplemented with 10% fetal bovine serum, 2 mM L-glutamine and 1% penicillin/streptomycin. MCF 10A cells were cultured in Dulbecco's Modified Eagle Medium:F12 (Sigma) supplemented with 5% horse serum heat-inactivated (Sigma), 20 ng/ml epidermal growth factor (Peprotech, Rocky Hill, NJ, USA) 0.5 mg/ml hydrocortisone (Sigma), 100 ng/ml cholera toxin (Sigma), 10 mg/ml insulin (Sigma) and 1% penicillin/streptomycin. Human umbilical vein endothelial cells were cultured in dulbecco's modified eagle medium:F12 supplemented with 5 ng/ml epidermal growth factor (Peprotech), 10 ng/ml basic fibroblast growth factor, 20 mg/ml heparin, 1 mg/ml hydrocortisone, 250 ng/ ml insulin, 1% penicillin/streptomycin and 2% fetal calf serum. All cells were maintained in a humidified atmosphere at 37 1C and 5% CO 2 .
Transient transfection PNT2-C2 cells, PC3 cells and DU145 cells were transfected using TransIT (Mirus, Madison, WI, USA). MCF-7 cells and MDA-MB-231 cells were transfected using Lipofectamine 2000 (Invitrogen, Grand Island, NY, USA). PC3 cells were transfected for luciferase assays using electroporation (250 V, 975 mF).
Luciferase assays PC3 cells were transiently transfected with reporter plasmids and either pMUG1-Myc-PRH or empty pMUG1 vector. After 24 h at 37 1C and 5% CO 2 , the cells were lysed and assayed for luciferase activity using a dual luciferase assay system (Promega) and a Berthold Technologies (Wildbad, Germany) luminometer. Renilla luciferase activity was used as an internal control for transfection efficiency.
PRH knockdown
Knockdown of PRH in PNT2-C2 cells was performed as described previously. 31 Knockdown of PRH in MCF-7 and MCF 10A cells was performed using an isopropyl b-D-1-thiogalactopyranoside-inducible PRH shRNA lentiviral construct (TRCN0000274008 Sigma). Cells were infected with the PRH shRNA lentiviral construct or a control scrambled shRNA lentivirus (SHC332) and after 48 h transduced cells were selected using puromycin. Stably transduced cell lines were grown in the presence of 1 mM isopropyl b-D-1-thiogalactopyranoside for 7 days to induce shRNA expression.
Cell migration assays
Cell monolayers on microscope coverslips were produced plating cells infected with Ad PRH or empty adenovirus (multiplicity of infection 50) and incubating the cells for 24 h at 37 1C and 5% CO 2 . After the addition of 1 mM hydroxyurea (Sigma) to inhibit cell division, a wound was created using a P1000 pipette tip. Pictures were taken using a Leica DMIRBE microscope (Leica, Wetzlar, Germany) with Hamamatsu (Hamamatsu City, Japan) charge-coupled device camera or a AMG EVOS XL CORE AMEX 1200, and the width and area of the wound was quantified using ImageJ software. 40 Chemotaxis assays were performed by seeding cells onto 8 mm Boyden chambers (Greiner Bio-One, Kremsmü nster, Austria) in Roswell Park Memorial Institute medium with 2% fetal bovine serum. The chambers were placed into 24-well plates containing Roswell Park Memorial Institute medium with 10% fetal bovine serum to create a serum gradient. In some experiments, cells were seeded in the presence of 3 mM ALK 4/5/7 kinase inhibitor SB-431542 (Sigma) or dimethyl sulfoxide. At the time points indicated, the cells were fixed with 4% paraformaldehyde (Fisher, Loughborough, UK) and stained with 2 mg/ml bisbenzimide (Sigma). Cells on the top and bottom of the membrane were counted using a Leica Q550 inverted epifluorescence microcope or Zeiss axioplan 2 (Zeiss, Gö ttingen, Germany).
Invasion assays were performed as above except that 50% Matrigel (BD Biosciences, Billeria, MA, USA) was added to the Boyden chambers and left at 37 1C for 1 h to solidify before seeding the cells. Extravasation assays were performed as described by Ma and Wang 41 except that PC3 cells were dissociated using Cell Dissociation Solution (Sigma) before seeding on the human umbilical vein endothelial cell layer.
Quantitative reverse transcriptase-mediated PCR RNA was purified 48 h after infection as described previously. 31, 42 Quantitative PCR was performed in triplicate with Endoglin and GAPDH (glyceraldehyde-3-phosphate dehydrogenase) primers (shown below). Data were analysed using Rotorgene 6 software (Corbett Research (Mortlake, Sidney, Australia); Rotorgene RG-3000) with GAPDH mRNA as an internal control.
Endoglin 5 
Western blotting
Whole-cell extracts were prepared using TRIS-EDTA-SDS (TES) buffer (1% SDS, 2 mM EDTA, 20 mM Tris-HCl pH 7.4) as described previously. 27 A rabbit polyclonal antibody was used to detect Endoglin (Abcam, Cambridge, UK). An in house PRH monoclonal antibody was produced by Abmart (Arlington, MA, USA). Lamin A/C and tubulin antibodies were from Santa Cruz (Dallas, TX, USA). Densitometry was performed using Quantity One 4.6 software (Bio-Rad, Hemel Hempstead, UK). Phosphorylated Smad3 (Ser423/ 425) was detected using a rabbit monoclonal antibody (Cell Signaling Technology, Danvers, MA, USA).
Chromatin immunoprecipitation
Cells were infected with Ad PRH or control virus (multiplicity of infection 50) and incubated for 24 h at 37 1C and 5% CO 2 before fixation in 1% formaldehyde for 8 min at 21 1C. Glycine was added to a final concentration of 125 mM, and then the cells were pelleted by microcentrifugation at 4 1C, resuspended in 130 ml lysis buffer (50 mM Tris-Cl pH 8.0, 10 mM EDTA, 1% SDS, 1 mM phenylmethylsulfonyl fluoride and protease inhibitor cocktail (Roche, Welwyn Garden City, UK)) and sonicated in a Biorupter (Diagenode, Denville, NJ, USA) for 20 min on high power at 4 1C. Dynabeads protein A magnetic beads (Invitrogen) were incubated with normal mouse IgG (Santa Cruz) or Myc9B11 (Cell Signalling Technology) in RIPA buffer (10 mM Tris-Cl pH 8.0, 140 mM NaCl, 1% v/v Triton X-100, 1 mM EDTA, 0.5 mM EGTA, 0.1% w/v SDS, 0.1% sodium deoxycholate) for 2 h at 4 1C on a rotary wheel. Chromatin lysates were incubated with antibody:bead complexes overnight at 4 1C on a rotary wheel. Beads were washed three times with 1 ml RIPA buffer, 1 ml RIPA containing 500 mM NaCl, 1 ml RIPA containing 0.5% NP-40 and twice with 1 ml TE buffer (10 mM Tris-Cl pH 8.0, 1 mM EDTA pH 8.0) and resuspended in elution buffer (20 mM Tris-Cl pH 7.5, 50 mM NaCl, 5 mM EDTA, 1% SDS). After digestion with proteinase K for 2 h at 68 1C DNA was obtained by phenol chloroform isoamyl alcohol extraction and precipitated before resuspension in TE. 
